Scapa Group PLC AGM Statement (3337G)
23 Luglio 2019 - 8:00AM
UK Regulatory
TIDMSCPA
RNS Number : 3337G
Scapa Group PLC
23 July 2019
23 July 2019
LEI No. 213800QIPVTK5ES5UU36
Scapa Group plc
AGM Statement
Scapa Group plc (AIM: SCPA) is holding its Annual General
Meeting at 10:30am today. At the meeting, Larry Pentz, Chairman of
Scapa Group, will provide the following update.
The Group's trading performance for the first quarter is in line
with the Board's expectations.
Q1 Statutory Basis Q1 Continuing Basis(1) Organic (excl Syst(2)
& CVT(3) )
Growth Growth Growth Growth Growth Growth
(Reported) (constant (Reported) (constant (Reported) (constant
FX) FX) FX)
------------ ----------- ------------ ----------- ------------ -----------
Healthcare Revenues 47.8% 41.5% 40.6% 34.6% 7.9% 3.5%
------------ ----------- ------------ ----------- ------------ -----------
Industrial Revenues 4.5% 2.8% 4.5% 2.8% 4.5% 2.8%
------------ ----------- ------------ ----------- ------------ -----------
Scapa Group Revenues 21.6% 18.4% 18.7% 15.6% 5.6% 3.1%
------------ ----------- ------------ ----------- ------------ -----------
The integration and consolidation projects are proceeding
according to plan and the Company continues to seek additional
opportunities to deliver long-term sustainable growth.
The Board considers Scapa to be well positioned to make further
progress against its strategic objectives and remains confident in
the Group's outlook.
(1) Excluding IFRS 15 provision release. A contract liability
provision was created as a result of the acquisition of Systagenix
in line with the requirements of IFRS 15 and this is excluded on a
'continuing' basis as it represents a non-cash item. This provision
will be released on a straight-line basis over a five-year period,
in line with the exclusive supply contract
(2) Systagenix
(3) ConvaTec
For further information:
Scapa Group plc Heejae Chae - Group Chief Executive Tel: 0161 301
Oskar Zahn - Chief Financial 7430
Officer
Numis Securities Limited Mark Lander, Richard Thomas Tel: 020 7260
(Nominated Adviser/Joint 1000
Broker)
------------------------------------ --------------
Berenberg Chris Bowman, Toby Flaux Tel: 020 3207
(Joint Broker) 7800
------------------------------------ --------------
FTI Consulting Brett Pollard, Victoria Foster Tel: 020 3727
(Media Relations) Mitchell 1000
------------------------------------ --------------
About Scapa Group plc
Scapa Group plc is a diversified Healthcare and Industrial
company focused on bringing best-in-class innovation, design and
manufacturing solutions to its customers.
Healthcare
Scapa Healthcare is the trusted strategic partner of choice for
the world's leading companies in Advanced Wound Care, Consumer
Wellness and Medical Device Fixation. We partner with the top
global MedTech companies to develop and manufacture innovative skin
friendly medical device fixation and topical solutions, from
inception through to market delivery, from our state-of-the-art
facilities.
For further information, please visit
www.scapahealthcare.com
Industrial
Scapa Industrial is a global supplier of bonding solutions and
manufacturer of adhesive-based products which offer meaningful
value in industrial applications due to their lightweight,
easy-to-apply properties. We are recognised for our unparalleled
range of products, including adhesive tapes, films and foams, and
we can engineer custom designs for even the most unique
applications.
For further information, please visit
www.scapaindustrial.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGMPGUGGMUPBGQP
(END) Dow Jones Newswires
July 23, 2019 02:00 ET (06:00 GMT)
Grafico Azioni Scapa (LSE:SCPA)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Scapa (LSE:SCPA)
Storico
Da Apr 2023 a Apr 2024
